阿帕他胺用于高危局限性前列腺癌根治性前列腺切除术后(Apa-RP)
Apa-RP 是一项在美国社区泌尿外科开展的多中心、开放标签、单臂 2 期研究,108 例高危局限性前列腺癌根治性前列腺切除术后患者接受 12 个周期阿帕他胺(每日 240 mg,28 天为一周期)联合雄激素剥夺治疗。24 个月无生化复发率为 100%(90% CI 93-100),治疗结束 12 个月后睾酮恢复(≥150 ng/dL)率为 77%(95% CI 66-85),107 例(99%)发生治疗中出现的不良事件,24 例(22%)为 3~4 级。
要点
- 高危局限性前列腺癌根治术后接受 12 周期阿帕他胺联合 ADT,24 个月无生化复发率为 100%(90% CI 93-100)。
- 治疗结束 12 个月后睾酮恢复率:≥50 ng/dL 为 96%(95% CI 88-98),≥150 ng/dL 为 77%(95% CI 66-85)。
- 107 例(99%)发生治疗中出现的不良事件,24 例(22%)为 3~4 级。
核心结论
- Apa-RP 中无生化复发生存率为 100%,77% 的患者在实际治疗结束后 12 个月内睾酮恢复(≥150 ng/dL),安全性可控。
- 这些结果提供概念验证,即 12 个周期阿帕他胺联合 ADT 的治疗强化可能成为高危局限性前列腺癌根治性前列腺切除术后患者的一种选择。
研究设计与样本
- Apa-RP(NCT04523207)是一项在美国社区泌尿外科开展的多中心、开放标签、单臂 2 期研究。
- 高危局限性前列腺癌根治性前列腺切除术后患者接受 12 个周期阿帕他胺(每日 240 mg;28 天为一周期)联合雄激素剥夺治疗(ADT)。
- 共入组 108 例患者,中位年龄 66.0 岁(范围 46.0-77.0 岁),中位术前 PSA 7.6 ng/mL(范围 2.2-62.7 ng/mL),基线睾酮中位 340.0 ng/dL(范围 43.0-939.0 ng/dL)。
- 主要终点为无生化复发生存率,次要终点包括睾酮恢复(≥150 ng/dL)和安全性。
主要发现
- 24 个月(计划治疗完成后 12 个月)无生化复发率为 100%(90% CI 93-100)。
- 治疗完成后 12 个月血清睾酮恢复率:≥50 ng/dL 为 96%(95% CI 88-98),≥150 ng/dL 为 77%(95% CI 66-85)。
- 总体上 107 例(99%)患者发生治疗中出现的不良事件,其中 24 例(22%)发生 3~4 级事件。
临床怎么用
- 作者认为,12 个周期阿帕他胺联合 ADT 的治疗强化可能成为高危局限性前列腺癌根治性前列腺切除术后患者的一种选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Approximately 25% to 50% of patients with high-risk localized prostate cancer experience biochemical recurrence (BCR) within 2 years of radical prostatectomy. The Apa-RP study (NCT04523207) investigated whether adjuvant apalutamide plus androgen deprivation therapy (ADT) in high-risk patients who have undergone radical prostatectomy improved BCR-free survival. MATERIALS AND METHODS: Apa-RP was a multicenter, open-label, single-arm, phase 2 study conducted in community urology practices in the US. High-risk patients who had radical prostatectomy received 12 cycles of apalutamide (240 mg daily; 28-day cycles) plus ADT. The primary end point was BCR-free survival. Secondary end points included testosterone recovery (≥150 ng/dL) and safety. RESULTS: One hundred eight patients were enrolled; median age was 66.0 years (range 46.0-77.0 years). Median preoperative PSA and baseline testosterone were 7.6 ng/mL (range 2.2-62.7 ng/mL) and 340.0 ng/dL (range 43.0-939.0 ng/dL), respectively. The BCR-free rate at 24 months (12 months after completion of planned therapy) was 100% (90% CI 93-100). Serum testosterone recovery rate (≥50 and ≥150 ng/dL) 12 months after treatment completion was 96% (95% CI 88-98) and 77% (95% CI 66-85), respectively. Overall, 107 (99%) patients experienced treatment-emergent adverse events, with 24 (22%) experiencing grade 3 to 4 events. CONCLUSIONS: In Apa-RP, BCR-free survival was 100% with 77% of patients having testosterone recovery (≥150 ng/dL) within 12 months of actual treatment completion and a manageable safety profile. These results provide proof of concept that treatment intensification with 12 cycles of apalutamide plus ADT could become an option for patients with high-risk localized prostate cancer who have undergone radical prostatectomy.
引用
- Shore N, Hafron J, Saltzstein D, et al. Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP). J Urol. 2024. PMID: 39088398. doi:10.1097/JU.0000000000004163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。